Pcar-19B Cells
Childhood Acute Lymphoblastic Leukemia
Explore 65 assets in Childhood Acute Lymphoblastic Leukemia →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Chongqing Precision Biotech Co., Ltd
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05334823CT.gov A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents | — | Recruiting | — | — | — |
NCT04888468CT.gov Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Childhood Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pcar-19B Cells (this asset) | Chongqing Precision Biotech Co., Ltd | P2 | B · 60 |
| Vincristine Sulfate | National Cancer Institute (NCI) | P3 | BBB |
| Cyclophosphamide | St. Jude Children's Research Hospital | P3 | BBB |
| Nivestim | St. Jude Children's Research Hospital | P3 | BBB |
| Cytarabine | Children's Oncology Group | P3 | BBB |
| Etoposide | Martin Schrappe | P3 | BBB |
| Pegaspargase | University of Chicago | P3 | BBB |
| Mercaptopurine Anhydrous | The Children's Hospital of Zhejiang University School of Medicine | P3 | BBB |
| Dexasone | Tanja Andrea Gruber | P3 | BBB |
+42 more in the Childhood Acute Lymphoblastic Leukemia cohort
Other indications for Pcar-19B Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | — | P2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pcar-19B Cells in Childhood Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pcar-19b-cells-childhood-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →